# Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

> **NCT00609492** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 245 (actual)

## Conditions studied

- Infections, Streptococcal
- Streptococcus Pneumoniae Vaccines

## Interventions

- **BIOLOGICAL:** GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
- **BIOLOGICAL:** Infanrix™-IPV/Hib

## Key facts

- **NCT ID:** NCT00609492
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-03
- **Primary completion:** 2008-11-10
- **Final completion:** 2009-03-30
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609492, "Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00609492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*